Bright future for NicOx after Pfizer glaucoma deal
March 10, 2006Research and Development
Shares in the French biotechnology company NicOx have soared after Pfizer snapped up the rights to its pipeline of ophthalmology …
New Novartis blindness treatment filed in Europe
March 2, 2006Sales and Marketing AMD, Lucentis, Novartis
Lucentis, a new treatment for neovascular age-related macular degeneration or ‘wet AMD’ has been submitted by Novartis to the European …
Herceptin challenges put patient safety at risk, says survey
March 2, 2006NHS managers have warned that the sidelining of the normal regulatory process for new medicines will put patient safety at …
GSK launches Europe’s first rotavirus vaccine
March 1, 2006Sales and Marketing
GlaxoSmithKline has launched Rotarix in Europe, the first ever marketed vaccine against rotavirus gastroenteritis, a common but potentially lethal condition …
Bioenvision’s leukaemia treatment gains positive opinion
March 1, 2006Sales and Marketing
Bioenvision has received a positive opinion from the European Medicines Agency for Evoltra (clofarabine), the first drug specifically developed for …
Erbitux closer to head and neck cancer approval
March 1, 2006Sales and Marketing
Merck KGaA's targeted cancer treatment Erbitux has moved a step closer to receiving EU approval to extend its licence to …
Novartis files new Hepatitis B treatment in Europe
February 28, 2006Sales and Marketing
Novartis has filed its new hepatitis B treatment telbivudine in the European Union, and says it represents a potential new …
ABPI chief calls for ‘new rules of engagement’
February 23, 2006Sales and Marketing
UK pharmaceutical industry leader Richard Barker has called for a fundamental rethink in the way the industry and the NHS …
Gene silencing technology to be used in war against bird flu
February 23, 2006Sales and Marketing
Cutting edge technology will be used develop new drugs to treat dangerous strains of influenza, including the threat of a …
Wyeth to open clinical trial ‘Super Centres’
February 23, 2006Research and Development
Wyeth has unveiled plans to streamline its drug development operations by opening a network of clinical trial 'Super Centres' around …
Pfizer’s new blood infection drug Eraxis approved
February 23, 2006Research and Development
Eraxis, a new treatment for potentially life-threatening fungal infections has been approved in the US.Pfizer's new antifungal is licensed to …
Sanofi’s wonder drug in limbo after regulator’s rejection
February 23, 2006Sales and Marketing
The future of Sanofi-Aventis' Acomplia is in serious doubt after regulators demanded more data for its use in weight loss, …
Pegasys recommended as front line hepatitis B treatment
February 23, 2006Sales and Marketing
Roche's Pegasys is set to be used more widely in England and Wales to treat hepatitis B following the release …
Tysabri trials restart after safety scare
February 20, 2006Research and Development
Clinical trials of Tysabri, the troubled multiple sclerosis treatment, are to begin again in the US after the FDA gave …
Avastin trial recruitment suspended after patient deaths
February 16, 2006Research and Development
Roche has stopped recruiting colon cancer patients who have undergone surgery to a trial of Avastin after four suddenly died.The …
WHO calls for action on counterfeits
February 16, 2006Manufacturing and Production
The World Health Organisation has called for 'immediate concrete' action against counterfeit medicines, which it says pose serious and sometimes …
Woman loses Herceptin court case
February 16, 2006Breast cancer patient Ann Marie Rogers has lost her court battle to be prescribed Herceptin on the NHS, in what …
Merck files novel diabetes drug Januvia
February 16, 2006Sales and Marketing
Merck has filed an innovative new diabetes treatment with the US regulator, and hopes the drug could be one of …
Working with NHS priorities
February 16, 2006Patients, health professionals and even some politicians have said it, now chief medical officer Nigel Crisp has confirmed it in …
Safety scare spells the end for Exanta
February 15, 2006Sales and Marketing
AstraZeneca is to abandon its novel anti-blood clotting drug Exanta after concerns emerged about its long-term safety.Just two years ago, …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
